Ethylene Glycol

Ethylene Glycol

SCHEMBL3679539

C=CCc1ccccc1OC=C.OCCO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.46
▸ ADRB2 P07550 5/20 0.43
▸ ADRB1 P08588 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HTR1A P08908 2/20 0.43
▸ ADRA2C P18825 2/20 0.43
▸ ADRB3 P13945 1/20 0.43
▸ SLC6A2 P23975 1/20 0.43
▸ BDKRB2 P30411 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ HTR2B P41595 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3807056 0.93 ALDH1A1 (0.47) ALDH1A1ADRB2ADRB1LMNAHTR1A
Ethylene Glycol SCHEMBL366742 0.85 ALDH1A1 (0.48) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL3391453 0.81 APOBEC3G (0.39) ALDH1A1ADRB2ADRB1LMNAHTR1A
Ethylene Glycol SCHEMBL5450377 0.80 GABRA1 (0.54) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL252950 0.79 KDM4E (0.57) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL7901091 0.78 ALDH1A1 (0.55) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL10394281 0.78 ALDH1A1 (0.46) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL11801031 0.78 KDM4E (0.47) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL1253668 0.78 ALDH1A1 (0.48) ALDH1A1ADRB2ADRB1LMNAHTR1A
SCHEMBL4540726 0.77 KDM4E (0.60) ALDH1A1ADRB2ADRB1LMNAHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519038-B2 Aldimines and compositions comprising aldimine SIKA TECHNOLOGY AG (CH) 2013-08-27 — — US disclosed
US-20120220736-A1 ALDIMINES AND COMPOSITIONS COMPRISING ALDIMINE SIKA TECHNOLOGY AG (CH) 2012-08-30 — — US disclosed
US-8252859-B2 Aldimines and compositions comprising aldimine SIKA TECHNOLOGY AG (CH) 2012-08-28 — — US disclosed
US-20100101455-A1 ALDIMINES AND COMPOSITIONS COMPRISING ALDIMINE SIKA TECHNOLOGY AG (CH) 2010-04-29 — — US disclosed
CN-101646707-A Aldimines with reactive groups comprising active hydrogen SIKA TECHNOLOGY AG CH 2010-02-10 — — CN disclosed
US-7629433-B2 Odor-less during hydrolytic deblocking, separation; for use as source for aldehydes; crosslinking agents SIKA TECHNOLOGY AG (CH) 2009-12-08 — — US disclosed
US-20090176944-A1 Aldimines Comprising Reactive Groups Containing Active Hydrogen, and Use Thereof SIKA TECHNOLOGY AG (CH) 2009-07-09 — — US disclosed
US-20090099333-A1 Compounds Containing Aldimine SIKA TECHNOLOGY AG (CH) 2009-04-16 — — US disclosed
EP-0091453-B1 PROCESS FOR THE PREPARATION OF POLYMER PARTICLES SINTEF (NO) 1991-03-13 — — EP disclosed
US-4530956-A Process for the preparation of aqueous dispersions of organic material and possible further conversion to a polymer dispersion when the organic material is a polymerizable monomer SINTEF (NO) 1985-07-23 — — US disclosed
EP-0091453-A1 PROCESS FOR THE PREPARATION OF POLYMER PARTICLES. SINTEF (NO) 1983-10-19 — — EP disclosed
WO-1983001453-A1 PROCESS FOR PREPARING AN AQUEOUS DISPERSION OF ORGANIC MATERIAL AND OPTIONALLY FURTHER CONVERSION TO A POLYMER DISPERSION UGELSTAD, JOHN 1983-04-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220736-A1 ALDIMINES AND COMPOSITIONS COMPRISING ALDIMINE ALDOA, ALDH7A1, ALDH3A1 ALDH1A1 6/4885ADRB2 2057/4885ADRB1 1905/4885
US-20100101455-A1 ALDIMINES AND COMPOSITIONS COMPRISING ALDIMINE ALDH7A1, ILK, ALDH3A1 ALDH1A1 5/4885ADRB2 2881/4885ADRB1 3273/4885
US-20090176944-A1 Aldimines Comprising Reactive Groups Containing Active Hydrogen, and Use Thereof ADH5, ADH1C, ADH1A ALDH1A1 5/4885ADRB2 456/4885ADRB1 356/4885
US-20090099333-A1 Compounds Containing Aldimine ALDH7A1, ALDH3A1, ALDH1A1 ALDH1A1 3/4885ADRB2 1294/4885ADRB1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback